Axil Capital's Past News
Portfolio Companies' Past News
Perseus Proteomics announced the end of Ph I Clinical Trial for Polycythemia Vera.
The core technology patent for Cellusion's development products was granted in Japan.
Cranebio exhibited at the International Society of Food and Environmental Viruses.
Jolly Good partners with ExaMD, a Health and Medical AI Company.
Juran Kato, CEO of GEXVal gave a lecture at CPHI Japan 2024.
Cranebio has released a reagent kit that detects Escherichia coli by luminescence.
Otsuka Pharmaceutical and Jolly Good began offering a new Emotional Awareness Training VR program through their joint venture, FACEDUO, a virtual reality (VR) program.
A paper on corneal regenerative medicine, a joint research between Cellusion and Keio University, was published in the Keio Medical Journal.
United Immunity secures ￥180 million by Debt Financing from Aozora Corporate Investment.
Perseuse Proteomics has been adopted as Tokyo Dtrategic Innovation Promotion Program.
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins.
Jolly Good Revolutionizes Healthcare with Immersive Service for Apple Vision Pro.
National Yangming Jiaotong University, a collaborative research partner of Elixiron Immunotherapeutics, published an article on fusion proteins for cancer treatment.
Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation.
© Axil Capital All Rights Reserved
